Organisation paid for research Program year 2023 Source: CMS Open Payments

West Virginia Univ

Neither a doctor nor a teaching hospital

Research payments

$159,776

23 payments

Through program year 2023, West Virginia Univ is reported as receiving $159,776 in research payments, across 23 payments.

By program year

3 rows
Year Kind Amount Payments
2023 Research $19,679 4
2022 Research $75,477 11
2019 Research $64,620 8

Breakdown

Who paid Research payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $103,137 17 payments
  2. AstraZeneca UK Limited $40,481 4 payments
  3. Alexion Pharmaceuticals, Inc. $16,158 2 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) $67,577 4 payments
  2. A Phase 3, randomized, double blind, placebo controlled, multicenter study of ravulizumab in adult participants who have thrombotic microangiopathy associated with a trigger $16,158 2 payments
  3. A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST) $13,150 1 payment
  4. This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC $11,923 2 payments
  5. A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY). $10,651 4 payments
  6. Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents $9,900 2 payments
  7. SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease $9,690 1 payment
  8. A Phase III Randomized Double-Blind Placebo Controlled Multi-Center International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN) $8,702 4 payments
  9. A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) $8,560 1 payment
  10. A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma $3,465 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record